
Analysis of H&E Images Using Deep Learning for the Prediction of Distant Metastatic Recurrence in Early Stage Melanoma

Yvonne Saenger MD Florence Irving Associate Professor of Medicine Columbia College of Physicians and Surgeons SITC Annual Meeting November 8, 2019

Disclosures

- Co-founder of Wasaba, a company with a focus on artificial intelligence based digital pathology biomarkers.
- Research funding from Amgen and Regeneron


Melanoma Staging is Critical but Imprecise...and Confusing



- Stage 2B worse than 3A. Stage 2C worse than stage 3A and 3B
- Complete staging frequently not performed
- Requires expert pathologists
- Provides estimates of survival that are difficult to plan care around (Stage IIB- 82%)
- Does not account for role of immune system in tumor progression


Gershenwald et al. CA Cancer Jrnl, 2017; 67(6) 474-92

Adjuvant Therapy Works...But Who Should Receive it?




- Window of benefit in Stage 3 is
 narrow
- Most will do well regardless
- \$200,000 per patient and serious toxicity risks
- Large trials in Stage II patients without biomarkers underway. Over 70% will never recur
- PDL1 staining is not predictive of benefit

The Tumor Micro-Environment is a Source of Biomarkers




Adapted from Balkwill, et al, 2012.


The Tumor Micro-Environment is a Source of Biomarkers



Adapted from Saenger et al CIR 2018; 6(4):491-493




Adapted from Saenger et al CIR 2018; 6(4):491-493 Abstraction of cell phenotypes as dots allows for mathematical analysis of spatial relationships




---- Higher Confidence Envelop

Paired Correlation Function Analysis Shows that Proximity of T cells to Tumor Cells Correlates with Recurrence Status



Overview of Our Approach



- Clinical and image data gathered from 3 medical centers (N=108)
- Cell-level information from QuPath (open-source pathology software)
- Image filtering and preprocessing of regional feature information
- Deep Learning Neural Network
- Majority voting from NN output

Training Population


(<i>n</i> = 108)	
Clinical characteristics	
Sex, n (%)	
Male	73 (67.6)
Female	34 (31.5)
Unknown	1 (0.9)
Age	
Known, <i>n</i> (%)	103 (95.4)
Median, n (range)	67 (22-96)
Unknown, <i>n</i> (%)	5 (4.6)
Location of tumor, n (%)	
Trunk	58 (53.7)
Extremity	48 (44.4)
Unknown	2 (1.9)
T-stage, n (%)	
T1a or T1b	18 (16.7)
T2a	11 (10.2)
T2b or T3a	41 (38.0)
T3b or T4a	22 (20.4)
T4b	12 (11.1)
Unknown	4 (3.7)
Stage, <i>n</i> (%)	
I	22 (20.4)
II	62 (57.4)
III	24 (22.2)

Pathologic characteristics

r uniologio onaluotonotico		
Depth (mm)		
Median, <i>n</i> (range)	2.30 (0.30-30)	
Ulceration, n (%)		
Absent	57 (52.8)	
Present	47 (43.5)	
Unknown	4 (3.7)	
Microsatellite lesions, n (%)		
Absent	101 (93.5)	
Present	6 (5.6)	
Unknown	1 (0.9)	
TILs		
Absent	9 (8.3)	
Non-brisk	67 (62.0)	
Brisk	23 (21.3)	
Unknown	9 (8.3)	
SLNB status, n (%)		
Completed	66 (61.1)	
Positive, n (% of completed)	20 (18.5)	
Negative, n (% of completed)	46 (42.6)	
Outcome characteristics		
Patient follow-up (months)		
Median, <i>n</i> (range)	58 (7-173)	
DMR, <i>n</i> (%)		
Distant recurrence	34 (31.5)	
No recurrence or local recurrence only	74 (68.5)	
OS, n (%)		
Alive (at least 2 years)	69 (63.9)	
Dead	39 (36.1)	
DSS, n (%)		
Alive or NED at death	78 (72.2)	
Median follow-up (months)	65	Saenge
Dead with melanoma	30 (27.8)	2019 Oc
Median follow-up (months)	34.5	2070 00


Saenger et al. Clin. Can. Res., 2019 Oct 21 Epub

Tiling and Tile Selection




Saenger et al. Clin. Can. Res., 2019 Oct 21 Epub

Patch Selection and Feature Generation




Saenger et al. Clin. Can. Res., 2019 Oct 21 Epub

Sequence Generation and Network analysis



Saenger et al. Clin. Can. Res., 2019 Oct 21 Epub

Validation on Two Independent Test Sets



Saenger et al. Clin. Can. Res., 2019 Oct 21 Epub

Acknowledgements

Saenger Laboratory Artificial Intelligence Project

- Michael Ross Moore B.S.
- Robyn Corrado-Gartrell M.D.
- Emanuelle Rizk B.A.
- Jaya Pradhan D.D.S
- Chen Yang MD

QmIF Project

- Robyn Corrado-Gartrell M.D.
- Thomas Hart B.S.
- Claire Audrey-Bayan M.D.
- Emanuelle Rizk B.S.
- Camden Esancy B.S.
- Grace Finkel B.S.
- Luke Barker B.S.
- Zoe Blake B.S.

Jing Wang M.D. Ph.D. Laboratory

- Param Kulkarni Ph,D.
- Eric Robinsom B.S.
- Isabel Friesner B.S.

Basil Horst MD Ph.D. Dermatopathology

David Rimm M.D. Ph.D. Laboratory

- Balazs Acs M.D. Ph.D.
- Pok Fai Wong Ph.D.

Raul Rabadan Ph.D. Laboratory

- Andrew X Chen B.S.
- Anthea Monod Ph.D.

Larisa Geskin M.D. Laboratory

• Megan Trager B.S.

Geisinger Dermatopathology

- Tammie Ferringer M.D.
- Bethany Rohr M.D.

Mount Sinai Dermatopathology

• Robert Phelps M.D.

NYU Dermatopathology

• Iman Osman M.D.

NYU Computational Biology

• CZ Chen Ph.D.

Yale Melanoma Group

Harriet Kluger MD

Columbia Melanoma Group

Bret Taback M.D. Ph.D. Gary Schwartz M.D. Richard Cavajal M.D.